CA87975M2085
© Newsfile
29.01.2026
TELO
LISTED
TSX
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
News Preview
Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Office...
Themefolio
Profiler
Peergroup
© Newsfile
19.01.2026
TELO
LISTED
TSX
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
News Preview
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESToronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") is pleased to announce a non-brokered private placement offering of secured convertible debentures ("D...
Themefolio
Profiler
Peergroup
© Newsfile
18.12.2025
TELO
LISTED
TSX
Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program
News Preview
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM) Minimal Residual Disease (MRD) clinical trial in collaboration with th...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
11.12.2025
TELO
LISTED
TSX
Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Dis...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
13.11.2025
TELO
LISTED
TSX
Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025
News Preview
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics, today announced that it will deliver an industry presentation at the 2025 Myeloma Canada MRD Testing Implementat...
Themefolio
Profiler
Peergroup
© Newsfile
09.10.2025
TELO
LISTED
TSX
American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
News Preview
Recognition highlights commercial potential of Telo's telomere-based MRD technology in the growing precision oncology marketToronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through it...
Themefolio
Profiler
Peergroup
© Newsfile
30.09.2025
TELO
LISTED
TSX
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
News Preview
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announces the relocation and expansion of its clinical laboratories and offices from the MaRS s...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
TELO
LISTED
TSX
Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease ("MRD")...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2025
TELO
LISTED
TSX
Telo Geonomics Announces Engagement of Investor Relations Service Provider
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that it has engaged Hayden IR, LLC. ("Hayden"), a U.S.-based investor relations consulting firm, to enhance the Company's investor relations strategy by increasing awareness of the Com...
Themefolio
Profiler
Peergroup
© Newsfile
24.07.2025
TELO
LISTED
TSX
International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - July 24, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the International Myeloma Society ("IMS") has accepted Telo Genomics' abstract submiss...
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2025
TELO
LISTED
TSX
Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President
News Preview
Toronto, Ontario--(Newsfile Corp. - June 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") has received a Statement of Claim filed by Sherif Louis, the former President of the Company, in the amount of approximately $530,000 for notice and bonuses that he claims are owed to him. Telo intends to file a st...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2025
TELO
LISTED
TSX
Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma
News Preview
Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of telomeres, is pleased to announce that it has initiated a multiple myeloma...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
27.05.2025
TELO
LISTED
TSX
Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)
News Preview
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, is pleased to announce that it has entered a new client agreement with Intellectual Property Ontario (IPON)....
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2025
TELO
LISTED
TSX
European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
News Preview
Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association ("EHA") has accepted Telo Genomics' abs...
Themefolio
Profiler
Peergroup
© Newsfile
10.04.2025
TELO
LISTED
TSX
Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
News Preview
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genom...
Themefolio
Profiler
Peergroup
© Newsfile
04.04.2025
TELO
LISTED
TSX
Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors
News Preview
Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors...
Themefolio
Profiler
Peergroup
© Newsfile
12.03.2025
TELO
LISTED
TSX
Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors
News Preview
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce Mr. Guido Baechler, has assumed the role of Executive Chairman...
Themefolio
Profiler
Peergroup
© Newsfile
27.02.2025
TELO
LISTED
TSX
Telo Genomics Announces Expanded Partnership with Trusted Health Advisors
News Preview
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") announces that, further to its engagement with Trusted Health Advisors ("THA"), as disclosed in a news release dated January 30, 2024, the Company has expanded and extended its agreement (the "Agreement") with...
Themefolio
Profiler
Peergroup
© Newsfile
23.12.2024
TELO
LISTED
TSX
Telo Genomics Closes Oversubscribed $2.5 Million Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release dated December 12, 2024, it has closed an over-subscribed, non-brokered private placement of 25,459,000 units ("Units") at a price of $0.10 per Unit f...
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2024
TELO
LISTED
TSX
Telo Genomics Announces Private Placement for up to $2 Million
News Preview
Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.10 per Unit for gross proceeds of up to $2,000,000 (the "Offering").Each Unit will consist of one common share of t...
Themefolio
Profiler
Peergroup
© Newsfile
19.11.2024
TELO
LISTED
TSX
Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)
News Preview
Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that its application to the...
Themefolio
Profiler
Peergroup
© Newsfile
30.10.2024
TELO
LISTED
TSX
Telo Genomics Expands its Strategic Collaboration with Mayo Clinic
News Preview
Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agree...
Themefolio
Profiler
Peergroup
© Newsfile
22.10.2024
TELO
LISTED
TSX
Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test
News Preview
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has presented the mos...
Themefolio
Profiler
Peergroup
© Newsfile
10.09.2024
TELO
LISTED
TSX
Telo Genomics Assessing MRD Status in TELO-DMRD Study
News Preview
Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its m...
Themefolio
Profiler
Peergroup
© Newsfile
13.08.2024
TELO
LISTED
TSX
Telo Genomics Receives CLIA Certification
News Preview
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the US Centres of Medica...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2024
TELO
LISTED
TSX
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP
News Preview
Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the College of American Pa...
Themefolio
Profiler
Peergroup
© Newsfile
12.06.2024
TELO
LISTED
TSX
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024
News Preview
Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presen...
Themefolio
Profiler
Peergroup
© Newsfile
30.05.2024
TELO
LISTED
TSX
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology
News Preview
Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology, is thrilled to announce that the manuscript titled, "Three-dimensional t...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2024
TELO
LISTED
TSX
Telo Genomics and Emery Pharma Announce Collaboration
News Preview
Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology is pleased to announce that the Company has signed a collaboration agreement with Emery...
Themefolio
Profiler
Peergroup
© Newsfile
10.04.2024
TELO
LISTED
TSX
Telo Genomics Receives Accreditation from College of American Pathologists
News Preview
Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the Accreditation Committ...
Themefolio
Profiler
Peergroup
© Newsfile
02.04.2024
TELO
LISTED
TSX
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
News Preview
Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that patient recruitment for it...
Themefolio
Profiler
Peergroup
© Newsfile
13.02.2024
TELO
LISTED
TSX
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
News Preview
Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treated patients. The study is being conducted in collaboration...
Themefolio
Profiler
Peergroup
© Newsfile
30.01.2024
TELO
LISTED
TSX
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
News Preview
Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has engaged Trusted Health Advisors (THA), a market leader specialized in guiding commercialization programs of innovative diagnostics products in the USA. THA will work with Telo's team to...
Themefolio
Profiler
Peergroup
© Newsfile
06.12.2023
TELO
LISTED
TSX
Telo Genomics Gears up for American Society of Hematology Conference
News Preview
Toronto, Ontario--(Newsfile Corp. - December 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, looks forward to attending the American Society of Hematology (ASH) annual meeting in San Diego this week. The Company will...
Themefolio
Profiler
Peergroup
© Newsfile
16.11.2023
TELO
LISTED
TSX
Telo Genomics Launches Physician Experience Program in the United States
News Preview
SMART Observational Study a Critical Step Toward Full Platform AvailabilityToronto, Ontario--(Newsfile Corp. - November 16, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, is excited to announce the initiation of their...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2023
TELO
LISTED
TSX
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists
News Preview
An Important Accreditation Milestone Achieved Towards Full Commercial AvailabilityToronto, Ontario--(Newsfile Corp. - November 7, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A), (the "Company" or "Telo"), a biotech company pioneering the most comprehensive A.I. based genomic medical testing, is excited to announce that the Coll...
Themefolio
Profiler
Peergroup
© Newsfile
01.11.2023
TELO
LISTED
TSX
American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting
News Preview
ASH is the world leader in supporting clinical and scientific hematology researchToronto, Ontario--(Newsfile Corp. - November 1, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") announces today that the American Society of Hematology (ASH) has accepted the results of TeloView-SMM technical repeatability validation f...
Themefolio
Profiler
Peergroup
© Newsfile
26.10.2023
TELO
LISTED
TSX
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
News Preview
Authorizes Telo to Offer its Laboratory Developed Tests ("LDT") from its Central LabToronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has passed all requirements and received its Certificate of Accreditation of ISO 15189. Im...
Themefolio
Profiler
Peergroup
© Newsfile
17.10.2023
TELO
LISTED
TSX
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM - An Important Commercial Milestone Achieved
News Preview
TeloView Analyses Telomeres to Accurately Predict and Characterize Multiple MyelomaToronto, Ontario--(Newsfile Corp. - October 17, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") today announced the launch of its TeloViewSMM to clinicians in the United States. Combining molecular biology and artificial intelligence...
Themefolio
Profiler
Peergroup
© Newsfile
12.10.2023
TELO
LISTED
TSX
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - October 12, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has participated in the International Myeloma Society ("IMS") annual meeting that took place in Athens, Greece during the last week of September 2023. Telo presented positive results in ass...
Themefolio
Profiler
Peergroup
© Newsfile
06.09.2023
TELO
LISTED
TSX
Telo Genomics Achieves Noteworthy International Standards Organization ("ISO") Regulatory Accreditation
News Preview
Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is proud to announce that it has successfully completed the final assessment and achieved ISO 15189 accreditation. ISO 15189 is the international standard specific for clinical laboratories. The ISO 15189 accr...
Themefolio
Profiler
Peergroup
© Newsfile
29.08.2023
TELO
LISTED
TSX
Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMM
News Preview
Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to provide an update on the planned launch of the TeloView®SMM (Smoldering Multiple Myeloma) assay in the fourth quarter of this year. The test will be introduced to clinicians as a Research Use Only (RUO...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2023
TELO
LISTED
TSX
Telo Genomics Announces Agreement for Strategic Advisory Services
News Preview
Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has entered into an agreement with Leede Jones Gable Inc. ("Leede") to compensate Leede for strategic advice provided in connection with the Company's recently closed $0.25 non-brokered private placement (...
Themefolio
Profiler
Peergroup
© Newsfile
14.06.2023
TELO
LISTED
TSX
Telo Genomics Completes Oversubscribed Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - June 14, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") announces that it has closed its previously announced non-brokered private placement ("Offering") of units (the "Units"). The Company issued a total of 11,335,500 Units at a price of $0.25 per Unit for gross proceeds of $2,...
Themefolio
Profiler
Peergroup
© Newsfile
12.06.2023
TELO
LISTED
TSX
Telo Genomics Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023
News Preview
Toronto, Ontario--(Newsfile Corp. - June 12, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") presented the results of its latest study on Friday June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting. This study, executed in conjunction with the Mayo Clinic, was conducted to confirm the util...
Themefolio
Profiler
Peergroup
© Newsfile
06.06.2023
TELO
LISTED
TSX
Telo Genomics Announces Private Placement Increased to $2,766,375 from Previously Announced Private Placement of $2,000,000
News Preview
Toronto, Ontario--(Newsfile Corp. - June 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has increased the size of its previously announced non-brokered private placement ("Offering") from up to $2 million in proceeds to $2,766,375 and 11,065,500 units (the "Units" or each a "Unit"...
Themefolio
Profiler
Peergroup
© Newsfile
05.06.2023
TELO
LISTED
TSX
Telo Genomics Presents Superior Results of Its Smoldering Multiple Myeloma Studies at ASCO 2023
News Preview
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented earlier today at the American Society of Clinical Oncology (AS...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2023
TELO
LISTED
TSX
Telo Genomics Announces Private Placement of Units
News Preview
Toronto, Ontario--(Newsfile Corp. - May 19, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.25 per Unit for gross proceeds of $2,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (a "Common...
Themefolio
Profiler
Peergroup
© Newsfile
04.05.2023
TELO
LISTED
TSX
Telo Genomics' Multiple Myeloma Drug Resistance Study Results Have Been Selected for Presentation at the 2023 European Hematology Congress
News Preview
Toronto, Ontario--(Newsfile Corp. - May 4, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that the abstract submitted to the European Hematology Association (EHA) 2023 annual congress was accepted for presentation and will be published in the official proceedings of the meeting. The abstract...
Themefolio
Profiler
Peergroup
© Newsfile
13.04.2023
TELO
LISTED
TSX
Telo Genomics Achieves a Major Milestone - Results of Smoldering Myeloma Study Accepted for Presentation at ASCO Annual Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - April 13, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) 2023 annual meeting was accepted for presentation and will be published in the official proceedings of the meeting. The...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2023
TELO
LISTED
TSX
Telo Genomics Advances to Final Stage of Achieving ISO Certification
News Preview
Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has recently completed the interim assessment of its systems and protocols for ISO 15189 certification with over 90% compliance. ISO 15189 is the international standard specific for clinical...
Themefolio
Profiler
Peergroup
© Newsfile
22.02.2023
TELO
LISTED
TSX
Telo Genomics Launches Multiple Myeloma Advisory Board at the American Society of Hematology Annual Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce the launch of our inaugural multiple myeloma clinical advisory board ("MM CAB"). The advisory group met at the American Society of Hematology ("ASH") meeting in New Orleans on December 13, 2022....
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2022
TELO
LISTED
TSX
Telo Genomics Appoints Kris Weinberg as Chief Executive Officer
News Preview
Toronto, Ontario--(Newsfile Corp. - December 12, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the appointment of Kris Weinberg as Chief Executive Officer ("CEO"), effective today. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President & Chief Technology Off...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2022
TELO
LISTED
TSX
Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual Meeting
News Preview
Toronto, Ontario--(Newsfile Corp. - December 8, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the formation of a multiple myeloma advisory board ("MM Advisory Board"). Driven by the success of TELO's recent clinical studies, announced on September 14, 2022, and as part of the Company's comm...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2022
TELO
LISTED
TSX
Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma
News Preview
Toronto, Ontario--(Newsfile Corp. - November 9, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce today that it is launching a clinical trial to monitor multiple myeloma disease progression in post-treated patients, by measuring and profiling the minimal residual disease ("MRD") in these patien...
Themefolio
Profiler
Peergroup
© Newsfile
18.10.2022
TELO
LISTED
TSX
Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory Board
News Preview
Toronto, Ontario--(Newsfile Corp. - October 18, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma ("MM") clinician, key opinion leader and medical diagnostics expert to establish and chair TELO's MM clinical ad...
Themefolio
Profiler
Peergroup
© Newsfile
14.09.2022
TELO
LISTED
TSX
Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
News Preview
Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its f...
Themefolio
Profiler
Peergroup
© Newsfile
17.08.2022
TELO
LISTED
TSX
Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples
News Preview
Toronto, Ontario--(Newsfile Corp. - August 17, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis of patient samples related to its multiple myeloma drug resistance clinical study. The patient samples were provided by the Mayo Clinic as part of an ongo...
Themefolio
Profiler
Peergroup
© Newsfile
13.07.2022
TELO
LISTED
TSX
Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma
News Preview
Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma ("MM") patients that are at high-risk of developing treatment resistance. This s...
Themefolio
Profiler
Peergroup
© Newsfile
06.07.2022
TELO
LISTED
TSX
Telo Genomics Completes Processing and Analysis of Smoldering Multiple Myeloma Patient Samples
News Preview
Toronto, Ontario--(Newsfile Corp. - July 6, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis component of its clinical study for TELO's lead prognostic test for smoldering multiple myeloma ("SMM"). The SMM patient samples were provided by the Mayo Cl...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
